title: Intravenous bortezomib for multiple myeloma that has progressed after subcutaneous bortezomib therapy.
authors.affiliation: Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan, junkuro@koto.kpu-m.ac.jp.
authors.forename: Junya
authors.initials: J
authors.lastname: Kuroda
authors.forename: Shinsuke
authors.initials: S
authors.lastname: Mizutani
authors.forename: Yuji
authors.initials: Y
authors.lastname: Shimura
authors.forename: Saori
authors.initials: S
authors.lastname: Maegawa
authors.forename: Hisao
authors.initials: H
authors.lastname: Nagoshi
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Chinen
authors.forename: Shotaro
authors.initials: S
authors.lastname: Tatekawa
authors.forename: Taku
authors.initials: T
authors.lastname: Tsukamoto
authors.forename: Yoshimi
authors.initials: Y
authors.lastname: Mizuno
authors.forename: Mio
authors.initials: M
authors.lastname: Yamamoto-Sugitani
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Kobayashi
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Matsumoto
authors.forename: Shigeo
authors.initials: S
authors.lastname: Horiike
authors.forename: Masafumi
authors.initials: M
authors.lastname: Taniwaki
mesh_terms: D061605:Administration, Intravenous; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001897:Boronic Acids / Q000008:administration & dosage*; D000069286:Bortezomib; D003907:Dexamethasone / Q000008:administration & dosage; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D011719:Pyrazines / Q000008:administration & dosage*
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D003907:Dexamethasone